Allergic conjunctivitis due to inhalant allergens and foods.
Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.
Dermatographism.
Anaphylaxis (as adjunct to epinephrine after acute manifestations controlled).
Allergic reactions to blood or plasma.
Action
Antagonizes the effects of histamine at H1 –receptor sites; does not bind to or inactivate histamine. Significant CNS depressant and anticholinergic properties.
Therapeutic Effect(s):
Decreased symptoms of histamine excess (sneezing, rhinorrhea, nasal/ocular pruritus, ocular tearing/redness and skin itching/urticaria).
Pharmacokinetics
Absorption: Well absorbed following oral administration
Distribution: Unknown
Metabolism and Excretion: Extensively metabolized by the liver, inactive metabolites excreted in urine. Negligible renal elimination of unchanged drug.
Half-life: 17 hr
TIME/ACTION PROFILE (plasma concentrations)
ROUTE
ONSET
PEAK
DURATION
PO-IR
unknown
unknown
4 hr
PO-ER
unknown
6.7 hr
12 hr
Contraindication/Precautions
Contraindicated in:
Hypersensitivity, including sulfite allergy
Lactation: Lactation (risk of death in children <2 yr);
Concurrent use of MAO inhibitors
Pedi: Children <2 yr (deaths have been reported).
Use Cautiously in:
Increased intraocular pressure or narrow angle glaucoma
Hyperthyroidism
Cardiovascular disease including hypertension
Stenosing peptic ulcer or pyloroduodenal obstruction
Symptomatic prostatic hypertrophy or bladder neck obstruction
OB: Safety not established in pregnancy;
Pedi: Younger children may be more sensitive to sedation or excitation
Geri: Older adults may be more susceptible to adverse reactions.
Begin with lowest dose and increase as needed and tolerated. Dose is based on condition severity and patient response.
PO Administer twice daily.
Use a calibrated measuring device for accurate dose; household tablespoon is not accurate and could lead to overdose. May be fatal if administered to children under 2 yr.
Patient/Family Teaching
Instruct patient to take medication as directed
May cause dizziness and drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known
Advise patient to avoid taking alcohol or other CNS depressants concurrently with this drug
Advise patient that good oral hygiene, frequent rinsing of mouth with water, and sugarless gum or candy may minimize dry mouth. Patient should notify dentist if dry mouth persists >2 wk
Rep: Instruct females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Monitor infants breastfeeding mothers taking carbinoxamine for drowsiness and irritability.
Evaluation/Desired Outcomes
Decrease in allergic symptoms
carbinoxamine is a sample topic from the Davis's Drug Guide.
Davis’s Drug Guide for Nurses App + Web from F.A. Davis and Unbound Medicine covers 5000+ trade name and generic drugs. Includes App for iPhone, iPad, and Android smartphone + tablet. Handbook covers dosage, side effects, interactions, uses. Davis Drug Guide PDF. Complete Product Information.